11:58 AM EST - Lobe Sciences Ltd : Today announced it has entered into a term sheet contemplating convertible note financing bearing interest at 15% per annum with a term of 12 months with Cantheon Capital for aggregate proceeds to the Company of up to USD$1,500,000 to conduct three clinical trials in Australia with newly announced partner iNGENu Pty Ltd.. The Convertible Notes will help fund the design and conduct of three clinical trials evaluating Lobe's proprietary psilocin analogues L-130 or L-131. Lobe Sciences Ltd
shares C.LOBE are trading up 5.2% at $0.10.
